Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102


MiR-378 promoted cell proliferation and inhibited apoptosis by enhanced stem cell properties in chronic myeloid leukemia K562 cells.

Ma J, Wu D, Yi J, Yi Y, Zhu X, Qiu H, Kong R, Lin J, Qian J, Deng Z.

Biomed Pharmacother. 2019 Apr;112:108623. doi: 10.1016/j.biopha.2019.108623. Epub 2019 Feb 20.


Overexpression of miR-574-3p suppresses proliferation and induces apoptosis of chronic myeloid leukemia cells via targeting IL6/JAK/STAT3 pathway.

Yang H, Zhang J, Li J, Zhao F, Shen Y, Xing X.

Exp Ther Med. 2018 Nov;16(5):4296-4302. doi: 10.3892/etm.2018.6700. Epub 2018 Sep 5.


MicroRNA-181a enhances the chemotherapeutic sensitivity of chronic myeloid leukemia to imatinib.

Wang G, Zhao R, Zhao X, Chen XI, Wang D, Jin Y, Liu XI, Zhao CI, Zhu Y, Ren C, Li M, Jin X, Zhang F, Zhong Z, Wang T, Li X.

Oncol Lett. 2015 Nov;10(5):2835-2841. Epub 2015 Sep 2.


MiR-124-3p/B4GALT1 axis plays an important role in SOCS3-regulated growth and chemo-sensitivity of CML.

Liu YX, Wang L, Liu WJ, Zhang HT, Xue JH, Zhang ZW, Gao CJ.

J Hematol Oncol. 2016 Aug 12;9(1):69. doi: 10.1186/s13045-016-0300-3.


MiR-152-3p promotes the development of chronic myeloid leukemia by inhibiting p27.

Wang L, Wang Y, Lin J.

Eur Rev Med Pharmacol Sci. 2018 Dec;22(24):8789-8796. doi: 10.26355/eurrev_201812_16646.


Novel agent nitidine chloride induces erythroid differentiation and apoptosis in CML cells through c-Myc-miRNAs axis.

Liu N, Li P, Zang S, Liu Q, Ma D, Sun X, Ji C.

PLoS One. 2015 Feb 3;10(2):e0116880. doi: 10.1371/journal.pone.0116880. eCollection 2015.


miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes.

Farhadi E, Zaker F, Safa M, Rezvani MR.

Tumour Biol. 2016 Oct;37(10):14117-14128. Epub 2016 Aug 12.


MiR-370 sensitizes chronic myeloid leukemia K562 cells to homoharringtonine by targeting Forkhead box M1.

Zhou M, Zeng J, Wang X, Guo Q, Huang T, Shen H, Fu Y, Wang L, Jia J, Chen C.

J Transl Med. 2013 Oct 23;11:265. doi: 10.1186/1479-5876-11-265.


Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia.

Zhao L, Li Y, Song X, Zhou H, Li N, Miao Y, Jia L.

Oncotarget. 2016 Sep 13;7(37):60074-60086. doi: 10.18632/oncotarget.11054.


Targeting of the signal transducer Smo links microRNA-326 to the oncogenic Hedgehog pathway in CD34+ CML stem/progenitor cells.

Babashah S, Sadeghizadeh M, Hajifathali A, Tavirani MR, Zomorod MS, Ghadiani M, Soleimani M.

Int J Cancer. 2013 Aug 1;133(3):579-89. doi: 10.1002/ijc.28043. Epub 2013 Mar 13.


The Critical Role of PTEN/PI3K/AKT Signaling Pathway in Shikonin-Induced Apoptosis and Proliferation Inhibition of Chronic Myeloid Leukemia.

Chen Y, Wang T, Du J, Li Y, Wang X, Zhou Y, Yu X, Fan W, Zhu Q, Tong X, Wang Y.

Cell Physiol Biochem. 2018;47(3):981-993. doi: 10.1159/000490142. Epub 2018 May 24.


miR-125b regulates cell progression in chronic myeloid leukemia via targeting BAK1.

Li Q, Wu Y, Zhang Y, Sun H, Lu Z, Du K, Fang S, Li W.

Am J Transl Res. 2016 Feb 15;8(2):447-59. eCollection 2016.


Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells.

Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, Muckenthaler MU, Ganser A, Eder M, Scherr M.

Blood. 2007 May 15;109(10):4399-405. Epub 2007 Feb 6.


MicroRNA-320a acts as a tumor suppressor by targeting BCR/ABL oncogene in chronic myeloid leukemia.

Xishan Z, Ziying L, Jing D, Gang L.

Sci Rep. 2015 Jul 31;5:12460. doi: 10.1038/srep12460.


microRNA-199a/b-5p enhance imatinib efficacy via repressing WNT2 signaling-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells.

Chen PH, Liu AJ, Ho KH, Chiu YT, Anne Lin ZH, Lee YT, Shih CM, Chen KC.

Chem Biol Interact. 2018 Aug 1;291:144-151. doi: 10.1016/j.cbi.2018.06.006. Epub 2018 Jun 8.


Overexpression of miR-202 resensitizes imatinib resistant chronic myeloid leukemia cells through targetting Hexokinase 2.

Deng Y, Li X, Feng J, Zhang X.

Biosci Rep. 2018 May 8;38(3). pii: BSR20171383. doi: 10.1042/BSR20171383. Print 2018 Jun 29.


MiR-570 inhibits cell proliferation and glucose metabolism by targeting IRS1 and IRS2 in human chronic myelogenous leukemia.

Zhao H, Liu F, Jia R, Chang H, Li H, Miao M, Wang H, Yang Z.

Iran J Basic Med Sci. 2017 May;20(5):481-488. doi: 10.22038/IJBMS.2017.8671.


miR-155 effectively induces apoptosis in K562 Philadelphia positive cell line through upregulation of p27kip1.

Edalati Fathabad M, Karimipoor M, Alizadeh S, Abdoli A, Atashi A, Sayadi M.

Bioimpacts. 2017;7(2):109-114. doi: 10.15171/bi.2017.14. Epub 2017 Apr 26.


HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1.

Bamodu OA, Kuo KT, Yuan LP, Cheng WH, Lee WH, Ho YS, Chao TY, Yeh CT.

Exp Cell Res. 2018 Sep 15;370(2):519-530. doi: 10.1016/j.yexcr.2018.07.017. Epub 2018 Jul 12.


Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.

Salati S, Salvestrini V, Carretta C, Genovese E, Rontauroli S, Zini R, Rossi C, Ruberti S, Bianchi E, Barbieri G, Curti A, Castagnetti F, Gugliotta G, Rosti G, Bergamaschi M, Tafuri A, Tagliafico E, Lemoli R, Manfredini R.

Oncotarget. 2017 Jul 25;8(30):49451-49469. doi: 10.18632/oncotarget.17706.

Supplemental Content

Support Center